CD8A and neoplasm: In GBM specifically, there have been many preclinical demonstrations of the effectiveness of checkpoint inhibition [136,137], showing reduced tumor burden, increased CD8 effector cell infiltration, and/or reduced Treg cell infiltration, depending on the agent administered.